We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Asthma Patients Cautioned on Melatonin Use

By HospiMedica staff writers
Posted on 07 Oct 2003
A study has found that people with asthma should consider limiting the use of melatonin as a sleep aid because higher levels of melatonin have been found to be associated with an overnight loss of lung function in asthma patients. More...
The findings were published in the September 2003 issue of the Journal of Allergy and Clinical Immunology.

Melatonin is an important regulator of circadian rhythms in the body, especially sleep. Because of its association with sleep, it has become a popular dietary supplement sold as a treatment for jet lag and insomnia. However, researchers found that patients with nocturnal asthma had the highest levels of melatonin and the greatest drop in lung function overnight. Peak levels of melatonin averaged 67.5 picograms/milliliter in nocturnal asthmatics, 61.1 pg/ml in non-nocturnal asthmatics, and 53.5 in healthy patients. Lung function dropped an average of 18.8% in nocturnal asthmatics, 5.1% in non-nocturnal asthmatics, and increased 1.5% in healthy controls.

"Those findings, on top of previous ones linking melatonin to inflammation, suggest that all patients with asthma should avoid using melatonin supplements until more is known about their safety,” said Rand Sutherland, M.D., M.P.H., who conducted the study along with colleagues at National Jewish Medical and Research Center (Denver, CO, USA).




Related Links:
National Jewish Medical and Research Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.